1267 related articles for article (PubMed ID: 24240112)
21. DNA repair mutations and outcomes in ovarian cancer--response.
Swisher EM; Norquist BM; Pennington KP; Rendi MH; Garcia RL
Clin Cancer Res; 2015 Feb; 21(3):659. PubMed ID: 25646182
[No Abstract] [Full Text] [Related]
22. DNA repair mutations and outcomes in ovarian cancer--letter.
Soslow RA
Clin Cancer Res; 2015 Feb; 21(3):658. PubMed ID: 25646181
[No Abstract] [Full Text] [Related]
23. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
[TBL] [Abstract][Full Text] [Related]
24. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
Sugino K; Tamura R; Nakaoka H; Yachida N; Yamaguchi M; Mori Y; Yamawaki K; Suda K; Ishiguro T; Adachi S; Isobe M; Yamaguchi M; Kashima K; Motoyama T; Inoue I; Yoshihara K; Enomoto T
Sci Rep; 2019 Nov; 9(1):17808. PubMed ID: 31780705
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
26. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM
Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535
[TBL] [Abstract][Full Text] [Related]
27. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract][Full Text] [Related]
28. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
[TBL] [Abstract][Full Text] [Related]
29. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
30. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
[TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
[TBL] [Abstract][Full Text] [Related]
32. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
[TBL] [Abstract][Full Text] [Related]
35. [Not Available].
Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
[TBL] [Abstract][Full Text] [Related]
36. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
[TBL] [Abstract][Full Text] [Related]
37. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J
Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857
[TBL] [Abstract][Full Text] [Related]
38. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
[TBL] [Abstract][Full Text] [Related]
39. Genetic characterization of early onset ovarian carcinoma.
Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
[TBL] [Abstract][Full Text] [Related]
40. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
